Collegium Pharmaceutical, Inc. (COLL) – What Are Analysts Thinking About This Stock?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $48.71.

COLL has been the subject of a number of recent analyst reports. Truist Financial initiated coverage on Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price objective for the company. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Zacks Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Piper Sandler reissued a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Finally, Oppenheimer began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price objective for the company.

Collegium Pharmaceutical Trading Down 0.3%

COLL stock traded down $0.08 during midday trading on Tuesday, reaching $21.97. The stock had a trading volume of 62,296 shares, compared to its average volume of 570,640. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a twelve month low of $21.43 and a twelve month high of $50.79. The firm has a market cap of $715.44 million, a price-to-earnings ratio of 17.70, a PEG ratio of 0.71 and a beta of 0.73. The business has a fifty day simple moving average of $24.87 and a two-hundred day simple moving average of $31.12.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.68 EPS. As a group, research analysts expect that Collegium Pharmaceutical will post 6.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COLL. Caitong International Asset Management Co. Ltd raised its position in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the period. Assetmark Inc. increased its stake in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares in the last quarter. Allworth Financial LP bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $175,000. Finally, EverSource Wealth Advisors LLC increased its stake in Collegium Pharmaceutical by 20.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 861 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.